OPUS GENETICS INC. - COMMON STOCK

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

09 Jul 2021 17:00:00 By Nasdaq GlobeNewswire

Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

30 Jun 2021 07:15:00 By Nasdaq GlobeNewswire

Ocuphire Announces Addition to the Russell Microcap® Index

11 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market

08 Jun 2021 16:10:00 By Nasdaq GlobeNewswire

Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors

08 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

04 Jun 2021 09:04:27 By Nasdaq GlobeNewswire

Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis

20 May 2021 07:30:00 By Nasdaq GlobeNewswire

Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia

18 May 2021 07:30:00 By Nasdaq GlobeNewswire

Ocuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia

12 May 2021 07:30:00 By Nasdaq GlobeNewswire

Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update

07 May 2021 08:00:00 By Nasdaq GlobeNewswire

Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting

22 Apr 2021 08:00:02 By Nasdaq GlobeNewswire

Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy

08 Apr 2021 08:31:26 By Nasdaq GlobeNewswire

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Apr 2021 17:10:53 By Nasdaq GlobeNewswire

Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint

15 Mar 2021 06:00:00 By Nasdaq GlobeNewswire

Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update

10 Mar 2021 16:30:00 By Nasdaq GlobeNewswire

Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol®

05 Mar 2021 08:44:07 By Nasdaq GlobeNewswire

Ocuphire to Participate in March Investor Conferences

04 Mar 2021 08:27:09 By Nasdaq GlobeNewswire

Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia

18 Feb 2021 08:53:31 By Nasdaq GlobeNewswire

Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021

11 Feb 2021 09:12:54 By Nasdaq GlobeNewswire

Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase

20 Jan 2021 07:00:00 By Nasdaq GlobeNewswire